Shanghai Bluesail Investment Co. offered to fund RMB 30 million to Fuzhou Dongze Medical Device Co. and hold its 30% share.

Fuzhou Dongze’s primary focus in on Kidney substitute treatment, man-made kidney treatment and in-depth hemodialysis treatment. In 2013, the company expects to reach RMB 33 million of revenue and RMB 4.2 million of net profit. With the funds provided, Dongze Medical plans to win a portion of China’s hemodialysis market by offering innovative hemodialysis product range and clinical treatment service.